Addressing The Uncertainties Of The IRA In Biopharma
Source: Life Science Leader
By Daniel Chancellor
In recent years, the biopharma industry has been anything but predictable. But the creation of the Inflation Reduction Act (IRA) of 2022 has added a new layer of uncertainty that reaches most corners of the industry.